University of Connecticut Studies Drug-Carrying Nanoparticles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

University of Connecticut Studies Drug-Carrying Nanoparticles


ePT--the Electronic Newsletter of Pharmaceutical Technology

Anson Ma, an assistant professor of chemical engineering at the University of Connecticut (UConn) has received a two-year National Science Foundation Early Concept Grant for Exploratory Research (EAGER) award to test the use of nanoparticles for drug delivery and to understand how nanoparticles flow in the bloodstream.

Nanoparticles are being considered to improve the delivery of cancer-fighting drugs to tumors while reducing the toxic side effects to normal tissues. “But blood is a very complicated fluid, and we don’t precisely know how the particles travel,” said Ma in a recent University press release.  The research team will build novel microfluidic devices that simulate the bloodstream and study the flow dynamics of nanoparticles within these simulated blood flows. The research will also consider the roles of blood constituents and of particle shape and size in delivering drugs to the tumor site and will investigate how certain factors like particle shape and surface chemistry influence the hydrodynamics of the nanoparticles.

“This project will be the first step in understanding the problem from an engineering perspective,” said Ma in the release. Ma and his student project team are collaborating with professors Leslie Shor from the Chemical Engineering department, Xiuling Lu from Pharmaceutical Sciences, and Suzy Torti from the UConn Health Center.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here